Bayer, NeuroCycle partner to advance pet allergy treatmentsSeptember 18, 2018Bayer Animal Health and NeuroCycle Therapeutics Inc. have signed a global license agreement to advance allergy treatment options for companion animals. As part of the license agreement, Bayer will develop and commercialize novel compounds based on NeuroCycle's intellectual property. "[This] agreement underlines our strategy to combine the know-how from creative startup companies like NeuroCycle with opportunities derived from Bayer's research," said Douglas Hutchens, DVM, PhD, Bayer Animal Health's …
SPONSORED CONTENTStart Treating Canine MMVD Patients at Stage B2Learn about early treatment with pimobendan for canine Stage B2 preclinical MMVD patients. + Learn More